The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute (NASDAQ: TOI) reported its Q4 and full-year 2024 financial results. Q4 highlights include consolidated revenue of $100 million, up 16.9% year-over-year, with a net loss of $13.2 million compared to $18.8 million in Q4 2023. The company achieved positive cash flow from operations of $4.2 million in Q4.

Key operational developments include a 12% reduction in SG&A expenses, new drug supplier agreements with improved discounts, and the launch of six new contracts covering over 250,000 lives. Value-based patient services increased by 15% from Q3 2024.

For full-year 2024, TOI reported consolidated revenue of $393 million, a 21.3% increase, though patient services revenue decreased 4% due to a lost contract. The company expects Q1 2025 Adjusted EBITDA of $(5) to $(6) million, citing seasonal factors such as drug price increases and lower encounter volumes.

The Oncology Institute (NASDAQ: TOI) has secured a $16.5 million private placement from accredited investors, including existing investors, management team members, and Board Directors. The placement is expected to close on March 26, 2025.

The agreement involves issuing units consisting of two common stock shares (or pre-funded warrants) and common warrants at $2.2084 per unit. Additionally, Deerfield Management Company will exchange approximately $4.1 million of TOI's senior secured convertible notes for 37,232.83 shares of common-equivalent preferred stock and warrants to purchase 1,861,642 common stock shares.

The proceeds will support organic growth and working capital needs. BTIG serves as the sole placement agent, with various legal firms advising different parties involved in the transaction.

The Oncology Institute (TOI), a leading value-based oncology group in the United States, has scheduled its fourth quarter and full year 2024 financial results announcement for March 25, 2025, after market close.

A conference call will follow at 5:00 p.m. Eastern Time on the same day. Investors can join via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or through a simultaneous webcast on the company's Investor Relations website. A replay will be available until April 1, 2025, accessible by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with passcode 13750791.

The Oncology Institute (NASDAQ: TOI) has announced key financial developments, including an amendment to its facility agreement with Deerfield Management Company and a partial debt reduction. The amendment removes the $40 million minimum cash covenant and lifts restrictions on equity offerings. TOI has paid down approximately $20 million of senior secured convertible notes and related interest.

The company has also reported significant progress in its growth initiatives, having secured three new capitation agreements in 2025, adding roughly 80,000 lives across California, Nevada, and Florida markets. Notably, Florida operations now manage over 200,000 lives under value-based agreements, including more than 50,000 under Medicare Advantage.

Florida Blue, Florida's leading health insurer, has launched a new comprehensive oncology care model for its myBlue members, partnering with Sanitas Medical Centers and The Oncology Institute (TOI). The program aims to provide faster access to high-quality cancer care through TOI's 14 locations in Central and South Florida, working alongside Sanitas's 60 medical centers.

The initiative features personalized treatment plans and seamless coordination between primary care physicians and oncologists. TOI oncology teams will collaborate with Sanitas primary care providers to support patients' overall health and mental well-being. The program is currently available in select areas across Florida with potential for expansion.

myBlue members can access this program through Florida Blue's HMO plan, with enrollment open until January 15 through the Marketplace or anytime for those qualifying for special enrollment.

The Oncology Institute (NASDAQ: TOI) reported Q3 2024 financial results with consolidated revenue of $99.9 million, up 21.8% year-over-year. The company saw a 79.9% increase in Dispensary segment revenue and signed 3 new capitation contracts across 2 states. Despite revenue growth, gross profit decreased 10.1% to $14.4 million, with margin falling to 14.4%. Net loss improved to $16.1 million from $17.4 million in Q3 2023. The company achieved a 6% reduction in SG&A expenses and expanded operations with first two clinics in Oregon. Cash position stood at $47.4 million as of September 30, 2024.

The Oncology Institute (NASDAQ: TOI) has received certification to administer Pluvicto therapy in their outpatient California radiation oncology practices. This radiopharmaceutical treatment for metastatic prostate cancer has traditionally been administered in hospital settings. TOI will become one of the few community-based practices on the West Coast offering radiopharmaceuticals in an outpatient setting, aiming to reduce hospitalization costs and provide value for patients and payors.

The Oncology Institute (NASDAQ: TOI) announced it will release its Q3 2024 financial results after market close on November 13, 2024, followed by a conference call at 5:00 p.m. Eastern Time. Investors can access the call by dialing 1-877-407-0789 (US) or 1-201-689-8562 (international). A replay will be available until November 20, 2024, accessible via 1-844-512-2921 (US) or 1-412-317-6671 (international) using passcode 13749308. A simultaneous webcast will be available on TOI's Investor Relations website.

The Oncology Institute (TOI) has joined Lantern's specialty care platform, expanding access to cancer care for Lantern members across TOI's community clinics in 5 states. The partnership aims to provide advanced cancer treatment while reducing financial burden for patients. TOI, with over 120 clinicians and 700 team members across 70+ clinic locations, serves a population of over 1.8 million patients. The collaboration focuses on delivering optimal outcomes and patient satisfaction through value-based oncology care, including clinical trials and transfusion services.